OCUGEN, INC. Increase (Decrease) in Other Operating Assets
OCUGEN, INC. (OCGN) reported Increase (Decrease) in Other Operating Assets of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2023-02-28
- OCUGEN, INC. increase (decrease) in other operating assets for the quarter ending 2022-12-31 was $0.00.
- OCUGEN, INC. increase (decrease) in other operating assets for the quarter ending 2022-09-30 was $0.00.
- OCUGEN, INC. increase (decrease) in other operating assets for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- OCUGEN, INC. increase (decrease) in other operating assets for the quarter ending 2021-09-30 was $0.00.
- OCUGEN, INC. increase (decrease) in other operating assets for fiscal 2022 was $0.00.
- OCUGEN, INC. increase (decrease) in other operating assets for fiscal 2021 was -$100.00K, a 196.15% decline from fiscal 2020.
- OCUGEN, INC. increase (decrease) in other operating assets for fiscal 2020 was $104.00K, a 54.19% decline from fiscal 2019.
- OCUGEN, INC. increase (decrease) in other operating assets for fiscal 2019 was $227.00K, a 318.80% increase from fiscal 2018.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month | Increase (Decrease) in Other Operating Assets 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-05 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | -$100.00K 10-K · filed 2023-02-28 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$100.00K 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | -$100.00K 10-Q · filed 2022-08-05 | ||||
| 2020-12-31 | $104.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $104.00K derived: sum of 2 quarters · filed 2022-02-28 | $104.00K 10-K · filed 2022-02-28 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-06 | ||||
| 2019-12-31 | $261.77K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $202.00K derived: sum of 2 quarters · filed 2022-02-28 | $227.00K 10-K · filed 2022-02-28 | $227.17K 10-K · filed 2020-03-27 | |
| 2019-09-30 | -$59.77K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$34.77K 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $25.00K 10-Q · filed 2020-08-14 | ||||
| 2018-12-31 | $50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $48.87K derived: sum of 2 quarters · filed 2020-03-27 | $54.20K 10-K · filed 2020-03-27 | ||
| 2018-09-30 | -$1.13K derived: 10-Q 9 month − 8-K/A 6 month · filed 2019-11-12 | $4.20K 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | $5.33K 8-K/A · filed 2019-10-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |